SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Charles Darwin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharles Darwin
Date of birth1809-02-12
IdentifiersMRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967
Document date1849-04-14
AuthorBernard Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week follow-up: results, gastroenterology consultation the same day, and a treatment plan. [S]

History of Present Illness

Mr. Darwin is a 40-year-old man evaluated six weeks ago for more than a year of episodes of nausea and repeated vomiting, who returns for his results and is seen by gastroenterology on the same day. His diary records three episodes since the first visit, each starting in the early morning or after a social evening, with half an hour to an hour of nausea, sweating, trembling hands, a racing heart, and a swimming head, then vomiting many times over 18 to 30 hours. He lay in a dark room and sipped water, and did not need emergency care. Between episodes he has wind and tires by the afternoon but does not vomit. His weight is steady. He confirmed again that he has never used cannabis and does not take long hot baths or showers during episodes. The blood and urine tests and ECG at the first visit were normal, the CT enterography two weeks later was normal, and the upper endoscopy two weeks ago was normal, with normal duodenal biopsies. [S]

ElementDetail
EpisodesThree in six weeks, each 18 to 30 hours, with a half-hour to one-hour prodrome
Between episodesWind and fatigue; no vomiting
CannabisNever used; no compulsive hot bathing
ResultsBlood tests, urinalysis, ECG, CT enterography, and upper endoscopy all normal

Review of Systems

SystemResultFinding
GastrointestinalPositiveEpisodic vomiting; wind between episodes; no blood in vomit or stool; no nocturnal pain
ConstitutionalPositiveTired after episodes; weight steady
CardiovascularPositiveRacing heart only in the prodrome; no chest pain or fainting
NeurologicalNegativeNo migraine headaches, weakness, or visual loss; swimming head only in the prodrome
PsychiatricPositiveWorry about episodes in company; no low mood most days; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amitriptyline 25 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-14 to 1849-04-28completedS
Sumatriptan 20 mg nasal spray, one spray at the first sign of an episodeOne spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a weekNasal route1849-04-14activeS
Ondansetron 8 mg orally disintegrating tablet at the first sign of an episodeDissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episodeOral route1849-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1849-04-14Body height183cmS
1849-04-14Body weight71.4kgS
1849-04-14Body mass index (BMI) [Ratio]21.3kg/m2S
1849-04-14Systolic blood pressure116mm[Hg]S
1849-04-14Diastolic blood pressure72mm[Hg]S
1849-04-14Heart rate76/minS
1849-04-14Respiratory rate14/minS
1849-04-14Body temperature36.7CelS
1849-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Physical Exam

Vital signs recorded on 1849-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell between episodes; weight 71.4 kg
CardiovascularRegular rhythm at 76 per minute; blood pressure 116/72 mmHg, with no drop on standing
AbdomenSoft, non-tender, no distension or succussion splash
NeurologicalCranial nerves and gait normal

Problems

ProblemClinical statusVerificationCodeProvenance
Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosisactiveprovisional R11.15S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory.
Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluationresolvedconfirmed R11.2S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementEpisode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed workEvery visitCompleted todayThree episodes in six weeks, 18 to 30 hours each, none needing emergency care; diary to continue
ExaminationRome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50)At diagnosis and with any change in patternCompleted todayCriteria met with gastroenterology; no red flags
LaboratoryBlood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serologyAt diagnosis between episodes; repeat only for an atypical episodeUp to dateAll normal six weeks ago, drawn between episodes, including lipase 32 U/L, TSH 1.6, morning cortisol 14.2, and tissue transglutaminase IgA 1.2 with normal total IgA; urine dipstick normal
ImagingUpper endoscopy and small-bowel imaging (CT enterography)Once at diagnosisCompleted todayCT enterography four weeks ago and upper endoscopy with duodenal biopsies two weeks ago reviewed: both normal
ImagingGastric emptying studyNot routine; only between episodes when gastroparesis is suspectedNot indicatedNo fullness, early satiety, or vomiting between episodes to suggest gastroparesis
Medication safetyECG with QTc on amitriptyline and ondansetron (below 450 ms in men)Baseline, at about 50 mg during titration, and at the target doseUp to dateBaseline QTc 412 ms six weeks ago; repeat at about 50 mg and at 75 mg
Medication safetyAmitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weightEach visit on treatmentCompleted todayBaseline before amitriptyline: weight 71.4 kg, no constipation, no dizziness on standing
SurveyMood and thoughts of self-harm on a tricyclic (PHQ-9)Each visit on treatmentUp to datePHQ-9 6 six weeks ago with item 9 scored 0; no thoughts of self-harm today
SurveyAnxiety screen (GAD-7)At diagnosis, then every three monthsUp to dateGAD-7 8 six weeks ago; repeat at three months
Medication safetyAbortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limitsEvery visitCompleted todaySumatriptan nasal spray and ondansetron dissolving tablets prescribed today, with timing, the one-repeat limit, and no more than six sprays a week explained
Self-managementIndividualized emergency department protocol letterAt diagnosis; update with any change in treatmentCompleted todayLetter written with gastroenterology: intravenous fluids with dextrose, intravenous ondansetron, lorazepam if needed, a dark quiet room, and sparing use of opioids
Self-managementTriggers: sleep, meals, travel, social stress, infectionsEvery visitCompleted todaySocial evenings, travel, short sleep, and long gaps without food identified from the diary
Self-managementCannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome)At diagnosis and yearlyCompleted todayNever used cannabis; no hot-bathing behavior
ExaminationComorbidities: migraine, orthostatic and autonomic symptoms, sleep disordersAt diagnosis and yearlyCompleted todayNo migraine headaches; no dizziness on standing; sleep regular except during episodes
Medication safetyMitochondrial supplements (coenzyme Q10, riboflavin)Conditional; consider with a partial responseNot indicatedDiscussed as a conditional option; he prefers to start with amitriptyline alone and add them only if the response is partial
Medication safetyAlternative prophylaxis (topiramate or aprepitant)Only if amitriptyline fails or is not toleratedNot indicatedFirst-line amitriptyline started today
Self-managementRelaxation training, meditation, or biofeedback; cognitive behavioral therapy offeredOngoingCompleted todayDiaphragmatic breathing taught; cognitive behavioral therapy offered
ExaminationWeight and hydrationEvery visitCompleted today71.4 kg, steady; well hydrated
ReferralGastroenterology consultationAt diagnosis, then as neededCompleted todaySeen today: Rome IV criteria met, provisional diagnosis, prophylaxis and abortive plan advised

Goal progress:

Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)

Follow-up: Portal messages at two and four weeks for the dose increases. Three-month review with the ECG, diary, and anxiety and mood screens. Next scheduled visit 1849-06-09: three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screen. [S]